Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder in the United States, characterized by both motor and non-motor symptoms. As current treatments primarily focus on dopamine deficiency and do not stop disease progression, alternative therapies are being explored. One such potential treatment is cannabis, particularly its constituent cannabidiol (CBD). Studies, like those discussed by Naturopathic Doctor Jade Stafano and neurology professor Maureen Leehey, MD, suggest CBD’s benefits in managing PD’s various symptoms. However, the adverse reactions and cognitive impairments associated with marijuana use cannot be overlooked.
The efficacy of medical marijuana in treating conditions beyond PD, such as HIV-related pain and Crohn’s disease, has also been reported. Yet, with the medical use of cannabis for PD outpacing the traditional drug-approval process, there remains a significant degree of uncertainty regarding its safety and effectiveness.
Could marijuana not only alleviate tremors but also address insomnia, pain, and depression associated with Parkinson’s? While some scientists posit its benefits, the pros and cons of marijuana in the treatment of PD still spark debate. Adverse effects and cognitive impairments, albeit temporary, have been noted as potential drawbacks.
Thus, while the popularity of cannabis for treating both motor and non-motor symptoms of PD is on the rise, fueled by media reports, the necessity for more rigorous research is evident. This literature review delves into the safety and efficacy of cannabis in treating motor symptoms and levodopa-induced dyskinesia in PD, highlighting the need for a cautious approach amidst growing enthusiasm.
To further understand the context, readers can refer to the detailed studies and findings through the following links: Stanford Parkinson’s Community Outreach, CU School of Medicine, IUPUI, Stanford University, Touro College of Pharmacy, IUPUI Study, Harvard Health, and Northwestern Scholars.